Elsevier

Biochimie

Volume 166, November 2019, Pages 84-93
Biochimie

Research paper
Imaging of extracellular cathepsin S activity by a selective near infrared fluorescence substrate-based probe

https://doi.org/10.1016/j.biochi.2019.03.013Get rights and content

Abstract

We designed a near-infrared fluorescent substrate-based probe (SBP), termed MG101, for monitoring extracellular cathepsin S (CatS) activity. We conceived a fused peptide hairpin loop-structure, combining a CatS recognition domain, an electrostatic zipper (with complementary charges of a polyanionic (D-Glu)5 segment and a polycationic (D-Arg)5 motif, as well as a Nsingle bond and Csingle bond terminal Förster resonance energy transfer pair (donor: AlexaFluor680; quencher: BHQ3) to facilitate activity-dependent imaging. MG101 showed excellent stability since no fluorescence release corresponding to a self-dequenching was observed in the presence of either 2 M NaCl or after incubation at a broad range of pH (2.2–8.2). Cathepsins B, D, G, H, and K, neutrophil elastase and proteinase 3 did not cleave MG101, while CatS, and to a lesser extent CatL, hydrolysed MG101 at pH 5.5. However MG101 was fully selective for CatS at pH 7.4 (kcat/Km = 140,000 M−1 s−1) and sensitive to low concentration of CatS (<1 nM). The selectivity of MG101 was successfully endorsed ex vivo, as it was hydrolysed in cell lysates derived from wild-type but not knockout CatS murine spleen. Furthermore, application of the SBP probe with confocal microscopy confirmed the secretion of active CatS from THP-1 macrophages, which could be abrogated by pharmacological CatS inhibitors. Taken together, present data highlight MG101 as a novel near-infrared fluorescent SBP for the visualization of extracellular active CatS from macrophages and other cell types.

Introduction

Cysteine cathepsins are papain-like proteases (C1 family, clan CA) [1], which consists of eleven members in humans: cathepsins B, C, F, H, K, L, S, O, V, W, and X [2]. Cysteine cathepsins have long been perceived as housekeeper enzymes, primarily involved in the recycling and degradation of proteins in lysosomes [3]. This view has evolved considerably with the demonstration of their distinctive involvement in specific biological processes (e.g. maturation of thyroid hormones, activation of neutrophil granule-associated proteases, bone resorption, matrix remodeling, pulmonary homeostasis or hair cycle control) and their identification as valuable prognostic biomarkers [2,[4], [5], [6], [7], [8], [9], [10], [11]]. Cathepsins are also deleterious contributors to a wide range of pathophysiological events (e.g. atherosclerosis, adiposity, osteoporosis, arthritis, metastasis, or fibrosis) [[12], [13], [14], [15], [16], [17], [18], [19], [20], [21]]. Cysteine cathepsins primarily localized in endosomal/lysosomal compartments, however they can be secreted and some of them are found extracellularly active (see for review [22]), favoring pathophysiological processes (e.g. invasiveness of transformed cells at the initial stage of tumor formation) [16,17]. Even though their precise role and individual contributions are still partially misunderstood, cysteine cathepsins have been validated as attractive and accurate targets for novel anti-protease drugs [12,[23], [24], [25], [26]].

Unlike most other family members (including cathepsin L) that display an ubiquitous expression profile, cathepsin S (CatS) expression is essentially restricted to professional antigen-presenting cells (APCs), embracing B cells, dendritic cells (DCs), monocytes and macrophages as well as non-professional APCs such as intestinal epithelial cells [27,28]. Although CatS and CatL display similar substrate specificities, CatL favors aromatic residues in the P2 position whereas CatS displays a preference for branched hydrophobic residues [29,30]. Moreover, CatS remains partly active at pH 7.4 while CatL is promptly inactivated at neutral or slightly alkaline pH [26]. CatS contributes to presentation and maturation of major histocompatibility complex class II molecules and DC motility [27,31,32]. An increase in CatS expression has been associated with several illnesses including cancer, atherosclerosis, cystic fibrosis, asthma, emphysema, colitis, irritable bowel syndrome and neuropathic pain [15,26,33,34]. Despite CatS is considered as a clinical biomarker and a relevant therapeutic target, its exact contribution to these diseases remains partly unsolved. The direct assessment of CatS activity within living cells and extracellular milieu using recently developed chemical tools will help to clarify the molecular mechanisms as well dysfunctions that occur during pathophysiological events. The two main strategies of probe design (inhibitor-based vs substrate-based probes) to profile protease activity were recently summarized by Turk and colleagues [35]. See also for examples some outstanding reviews: [[36], [37], [38], [39]]. Both types of probes have been successfully used in a broad range of applications from cell assays to animal models. Briefly, inhibitory activity-based probes (ABPs) react with proteases in stoichiometric ratios. They consist of a reactive functional group (electrophilic warhead) that binds covalently to the active site (via its catalytic nucleophilic residue) of the protease, coupled to a targeting sequence, and a reporter group for visualization. ABPs do not enable signal amplification, which can result in low-intensity signals, but they accurately pinpoint the protease activity. By contrast, substrate-based probes (SBPs) usually contain a peptide (or peptidomimetic) substrate backbone linked to an appropriate tag and a quencher group. Cleavage of SBP by its target can generate strong reporter signal amplification, since a single protease molecule converts several SBPs. However, released reporters may diffuse and could lead to unfocused images.

During the last decade, distinct chemical probes have been developed for assessment of CatS activity, such as a CatS-activatable dendrimer [40,41], peptidyl diazomethyl ketones [37,42], a coumarin-labeled vinyl sulfone tripeptidomimetic [43], “reverse design"-based CatS probes [[44], [45], [46]], NIRF (near infrared fluorescence) non-peptidic quenched ABPs [47,48], and dual-modality (optical and PET/CT) probes [49]. However, given that the extracellular activity of CatS is usually associated with pathophysiological events (e.g. cancer, atherosclerosis or neuropathic pain [26]), a CatS selective probe to assess only secreted active CatS is a highly attractive tool to further understand the complex biology of this protease.

The objective of the present work was to conceive and evaluate a non cell-permeable near infrared fluorescent SBP for monitoring only extracellular CatS activity. We therefore designed a peptide hairpin loop-like structure that consists of a CatS selective substrate sequence and an electrostatic zipper, forcing a close proximity of a Nsingle bond and Csingle bond terminal FRET couple (donor: AlexaFluor680; quencher: BHQ3) [50]. Kinetics constants, signal sensitivity, and physicochemical parameters of the NIRF probe, subsequently referred to as MG101, were determined in vitro. Selectivity of MG101was assessed ex vivo by using spleen lysates from CatS knockout (Ctss−/−) or wild-type (C57/Bl6 background) mice. Furthermore, the ability of MG101 to specifically detect extracellular CatS activity in cellulo was endorsed using human THP-1 macrophages.

Section snippets

Enzymes, substrates and inhibitors

Human cathepsins B, L and H were purchased from Calbiochem (VWR International, Pessac, France). Human CatK was a kind gift from Prof Dieter Brömme (University of British Columbia, Vancouver, Canada). Recombinant human CatS was produced as previously described [51]. Human neutrophil elastase (HNE) and proteinase 3 (PR3) were provided by BioCentrum (Krakow, Poland). Human cathepsin G was from ICN Pharmaceuticals (Costa Mesa, CA, USA). Human aspartic CatD was obtained from Sigma–Aldrich (St

Design and characterization of the intramolecularly quenched fluorescent CatS substrate-based probe MG101

The substrate sequence (i.e. CatS recognition domain) was derived from a substrate previously devised for quantification of CatS activity in APCs [55]. The electrostatic zipper corresponded to a short double strand consisting of complementary charges of a polyanionic (D-Glu)5 segment and a polycationic (D-Arg)5 motif) covalently linked to the CatS recognition peptide via a (D-Ala)2 spacer (see schematic representation: Fig. 1). A maleimide functionalized fluorescent dye (AlexaFluor680) was

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

LHVS, an irreversible inhibitor of cathepsin S, and human cathepsin K were kind gifts from Prof James H. McKerrow (Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, USA) and from Prof Dieter Brömme (University of British Columbia, Vancouver, Canada), respectively. We acknowledge Dr Guillaume Gabant and the mass spectrometry platform of CBM for the MS analyses.

References (68)

  • M. Vizovišek et al.

    Protease specificity: towards in vivo imaging applications and biomarker discovery

    Trends Biochem. Sci.

    (2018)
  • L.E. Edgington et al.

    Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes

    Curr. Opin. Chem. Biol.

    (2011)
  • C.S. Hughes et al.

    Strategies for detection and quantification of cysteine cathepsins-evolution from bench to bedside

    Biochimie

    (2016)
  • J. Chin et al.

    Near-infrared fluorescent probes for peptidases

    Coord. Chem. Rev.

    (2018)
  • A. Veilleux et al.

    Probing cathepsin S activity in whole blood by the activity-based probe BIL-DMK: cellular distribution in human leukocyte populations and evidence of diurnal modulation

    Anal. Biochem.

    (2011)
  • D. Caglič et al.

    Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation

    Bioorg. Med. Chem.

    (2011)
  • M. Verdoes et al.

    A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages

    Chem. Biol.

    (2012)
  • M. Galibert et al.

    Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S

    Eur. J. Med. Chem.

    (2018)
  • T. Garenne et al.

    Active site labeling of cysteine cathepsins by a straightforward diazomethylketone probe derived from the N-terminus of human cystatin C

    Biochem. Biophys. Res. Commun.

    (2015)
  • N. Lützner et al.

    Quantifying cathepsin S activity in antigen presenting cells using a novel specific substrate

    J. Biol. Chem.

    (2008)
  • S. Futaki et al.

    Arginine-rich Peptides: an abundant source of membrane-permeable peptides having potentiel as carriers for intracellular protein delivery

    J. Biol. Chem.

    (2001)
  • C. Bechara et al.

    Cell-penetrating peptides: 20 years later, where do we stand?

    FEBS Lett.

    (2013)
  • V. Hervé-Grépinet et al.

    Extracellular catalase activity protects cysteine cathepsins from inactivation by hydrogen peroxide

    FEBS Lett.

    (2008)
  • F. Chellat et al.

    Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles

    Biomaterials

    (2005)
  • N.D. Rawlings et al.

    The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database

    Nucleic Acids Res.

    (2018)
  • F. Lecaille et al.

    Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design

    Chem. Rev.

    (2002)
  • B. Turk et al.

    Protease signalling: the cutting edge

    EMBO J.

    (2012)
  • G. Lalmanach et al.

    Cysteine cathepsins and caspases in silicosis

    Biol. Chem.

    (2006)
  • C. Taggart et al.

    Protean proteases: at the cutting edge of lung diseases

    Eur. Respir. J.

    (2017)
  • T. Reinheckel et al.

    Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L

    Biol. Chem.

    (2001)
  • B. Friedrichs et al.

    Thyroid functions of mouse cathepsins B, K, and L

    J. Clin. Investig.

    (2003)
  • O. Vasiljeva et al.

    Emerging roles of cysteine cathepsins in disease and their potential as drug targets

    Curr. Pharmaceut. Des.

    (2007)
  • B. Korkmaz et al.

    Therapeutic targeting of cathepsin C: from pathophysiology to treatment

    Pharmacol. Ther.

    (2018)
  • M. Vizovišek et al.

    Cysteine cathepsins in extracellular matrix remodeling: extracellular matrix degradation and beyond

    Matrix Biol.

    (2018)
  • Cited by (10)

    • Cathepsins in the extracellular space: Focusing on non-lysosomal proteolytic functions with clinical implications

      2023, Cellular Signalling
      Citation Excerpt :

      Based on the significant overlap between the distributions of CatL and CatB in MDA-MB-231 cells (an epithelial, human breast cancer cell line), a HyCoSuL-derived small-molecule probe for determining CatL activity in live cells was created, which would presumably be beneficial for detecting tumor functional states [100]. In addition to its tight link with cancers and cardiovascular illness, the most remarkable characteristic of CatS is its intimate interaction with antigen-presenting cells (macrophages and dendritic cells) that exhibit cellular specificity [101,102]. Earlier probes were designed to merely detect different functions, and more recently there is interest in the design and manufacture of near-infrared quenching activity-based probes that can also specifically target the CatS that is highly expressed in immune cells or be used to treat illnesses in specific sectors.

    • Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential

      2022, Molecular Aspects of Medicine
      Citation Excerpt :

      Despite these redundancies, studies with chemical probes and knockdown/knockout studies have clearly demonstrated non-redundant roles for CTSS in specific diseases/conditions, that warrant further investigation of its potential as a therapeutic target. This has stimulated interest from the research community in the usefulness of this protease, facilitated by the development of more sensitive and specific CTSS substrates, which have aided in discriminating CTSS activity from other proteases (Lützner and Kalbacher, 2008; van Dalen et al., 2021; Wartenberg et al., 2019; Wilkinson et al., 2015b). Whilst initial studies highlighted vital roles in degrading damaged or surplus proteins and in MCH-II antigen presentation, more recent investigations have elucidated novel roles across some of the most burdensome conditions both in terms of individual morbidity and mortality but also society at large, including cancer, cardiovascular disease, and chronic inflammatory disorders.

    • Tumor cell- and microenvironment-specific roles of cysteine cathepsins in mouse models of human cancers

      2020, Biochimica et Biophysica Acta - Proteins and Proteomics
      Citation Excerpt :

      This requires new cell-impermeable pharmacological tools, such as the DARPins developed for extracellular CtsB [97] or antibodies targeting CtsS [98], in combination with extracellular protease imaging to determine the hot spots of protease activity in cancer microenvironments [99].

    View all citing articles on Scopus
    1

    MW & AS: Equal contribution to the work.

    2

    Current address: GENEPEP, Saint-Jean-de-Védas, France.

    3

    Current address: Innate Pharma SA, Marseille, France.

    View full text